Radient Pharmaceuticals Corporation engages in the research, development, manufacture, sale, and marketing of medical diagnostic products. It offers Onko-Sure, a proprietary in-vitro diagnostic cancer test, which is used for the detection and/or monitoring of the presence of colon, rectal, lung, stomach, tongue, ovarian, uterine, liver, pancreatic, bladder, brain, esophageal, hematological, breast, prostate, cervical, thyroid, lymphoma, and trophoblast cancers. The company sells its products through distributors to hospitals, clinical laboratories, clinics, and other health care organizations. It operates primarily in the United States, Canada, China, Chile, Europe, India, Korea, Taiwan, Vietnam, and Japan. The company was formerly known as AMDL, Inc. and changed its name to Radient Pharmaceuticals Corporation in September 2009. Radient Pharmaceuticals Corporation was founded in 1988 and is headquartered in Tustin, California.